Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Holding STRO?
Track your performance easily
STRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.45 - $6.13
Previous Close$2.65
Volume723.06K
Average Volume (3M)667.06K
Market Cap
$218.52M
Enterprise Value-$144.87M
Total Cash (Recent Filing)$388.25M
Total Debt (Recent Filing)$24.86M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Mar 26, 2025EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding82,458,725
10 Day Avg. Volume974,505
30 Day Avg. Volume667,061
Standard Deviation0.19
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.98
Price to Sales (P/S)1.38
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.90
Enterprise Value/Gross Profit-0.94
Enterprise Value/Ebitda1.80
Forecast
1Y Price Target
$10.83Price Target Upside308.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Sutro Biopharma News
PremiumCompany Announcements
Sutro Biopharma Advances Pipeline Amid Financial Losses
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMultiple partners are providing non-dilutive capital, which strengthens Sutro's financial position without affecting current shareholders.
Pipeline DevelopmentSutro Biopharma plans to submit three INDs from the next-generation ADC pipeline over the next three years, indicating a strong pipeline development strategy.
Product ExpansionLuvelta is expanding into NSCLC and has best-in-class potential as a treatment for low-medium FolRα expressing PROC.
Bears Say
Clinical DataPrior exposure to bevacizumab reduced the efficacy, with bev naive patients achieving a 50% ORR and bev exposed patients achieving a 22% ORR.
Financial PerformanceThere is a 42% potential downside with a bear case price of $2.
Safety Concerns44% of patients experienced TRAEs leading to discontinuation, which compares to 38% for mirv+bev.
---
Ownership Overview
8.81% Insiders
10.38% Mutual Funds
31.30% Other Institutional Investors
39.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $2.45 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Currently, no data Available
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 26, 2025 which is in 88 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.145.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -$0.83.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 82,458,725 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -12.879%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Among the largest hedge funds holding Sutro Biopharma Inc’s share is Deerfield Management Company, LP. It holds Sutro Biopharma Inc’s shares valued at 1M.
---
Sutro Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.83 (308.68% Upside)
$10.83 (308.68% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 422.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.71%
12-Months-Change
Fundamentals
Return on Equity
-110.89%
Trailing 12-Months
Asset Growth
4.66%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.83
▲(308.68% Upside)
Technical Analysis
Best Analysts Covering STRO
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-20.52%
reiterated a buy rating last month
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -20.52% per trade.
---